Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Abatacept is a fusion protein consisting of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1 and is likely to be eliminated via proteolytic catabolism throughout the body. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, when used for the prophylaxis of acute graft versus host disease, coadministration can increase the risk of developing anaemia. Monitor as per treatment protocols. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Abiraterone has multiple metabolic pathways and is an inhibitor of CYP2D6. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acalabrutinib is a CYP3A4 and P-gp substrate. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aclidinium bromide is rapidly and extensively hydrolyzed (non-enzymatic and enzymatic transformation by esterases and butylrylcholineesterases) to its pharmacologically inactive metabolites with only a minor role for CYP metabolism. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Adalimumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab. Additionally, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Afatinib is mainly eliminated unchanged in the faeces. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alectinib is metabolized by CYP3A4 to an active metabolite (M4), which is also metabolized by CYP3A4. Atezolizumab and bevacizumab are primarily metabolized through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alemtuzumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab. Additionally, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Osteonecrosis of the jaw has been reported in an increasing number of renal cell cancer patients since the use of combined therapies consisting of nitrogen-containing bisphosphonates and antiangiogenic targeted agents. This suggests that angiogenesis suppression might increase the risk of osteonecrosis of the jaw when coadministered with bisphosphonates.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alpelisib is primarily metabolized by enzymatic hydrolysis to an inactive metabolite, with a minor contribution from CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amivantamab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Anakinra, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab. Additionally, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anastrozole is metabolized by multiple enzyme pathways and a clinically significant interaction is not expected. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Apalutamide is metabolized by CYP2C8 and CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. [Note, use of apalutamide in severe hepatic impairment is not recommended in the European SmPC.]

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Asciminib is metabolized by several pathways, including CYP3A4, UGT2B7 and UGT2B17. Atezolizumab and bevacizumab are primarily metabolized through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. Additionally, immunosuppressants should not be used before starting atezolizumab and bevacizumab, as they may interfere with the efficacy of atezolizumab.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Limited data suggest that asparaginase is likely to be eliminated by the reticulo-endothelial system. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Avapritinib is predominantly mediated by CYP3A4 and to a minor extent by CYP2C9. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. Additionally, immunosuppressants should not be used before starting atezolizumab and bevacizumab, as they may interfere with the efficacy of atezolizumab .

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Avelumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Axitinib is a metabolized by CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Azacitidine undergoes spontaneous hydrolysis and deamination mediated by cytidine deaminase. Urinary excretion is the primary route of elimination of azacitidine and/or its metabolites. Following cellular uptake, azacitidine is sequentially phosphorylated. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied. Azathioprine is converted to 6-mercaptopurine which is further metabolized to natural purines. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. CYP3A4 contributes to less than 10% to baricitinib overall metabolism. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Basiliximab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Belantamab mafodotin is a humanized monoclonal antibody conjugated to maleimidocaproyl monomethyl auristatin F (mcMMAF). mcMMAF has limited metabolic clearance. The monoclonal antibody component, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Belimumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bendamustine is metabolized by multiple routes including hydrolysis (main), glutathione conjugation and hepatic metabolism via CYP1A2. Atezolizumab and bevacizumab are primarily metabolized through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. Additionally, immunosuppressants should not be used before starting atezolizumab and bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bexarotene is mainly metabolized by CYP3A4. Atezolizumab and bevacizumab are primarily metabolized through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bicalutamide is metabolized by CYP3A4 and UGT1A9. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bimekizumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab. Additionally, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bismuth subsalicylate is largely hydrolysed in the stomach to form salicylic acid, which is rapidly absorbed, and insoluble bismuth salts, which are excreted unchanged in faeces. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Blinatumomab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bortezomib is metabolized by and is a weak inhibitor of CYPs 1A2, 2C9, 2C19, 2D6, and 3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Bosutinib is metabolized principally by CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brentuximab vedotin releases the active species MMAE within the tumour cell; MMAE is a substrate of CYP3A4 and possibly CYP2D6 and a weak inhibitor of CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Brimonidine is metabolized mainly by aldehyde oxidase. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Brodalumab is degraded into small peptides. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab. Additionally, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Canakinumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Population PK studies of bevacizumab and capecitabine predicted no clinically relevant effect on either drug. Capecitabine is metabolized by CYP2C9. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Coadministration of bevacizumab and carboplatin/paclitaxel did not affect bevacizumab or carboplatin pharmacokinetics. Carboplatin is excreted primarily by renal glomerular filtration. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. [Note: the bevacizumab Summary of Product Characteristics carries a specific warning for neutropenia, febrile neutropenia, or infection with or without severe neutropenia in patients coadministered bevacizumab and platinum-based therapies.]

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carfilzomib is extensively metabolised by peptidase and epoxide hydrolase, with minimal metabolism by CYP enzymes and is also a substrate of P-gp. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cemiplimab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cetuximab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Very little has been described about chlorambucil metabolism in humans but CYP450 enzymes are not involved. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ciclosporin is a substrate and inhibitor of P-gp and CYP3A4, and inhibits hepatic uptake transport. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Population PK studies of bevacizumab and cisplatin/gemcitabine predicted no clinically relevant effect on bevacizumab or cisplatin pharmacokinetics. Cisplatin is eliminated renally via OCT2 and MATE1. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. [Note: the bevacizumab Summary of Product Characteristics carries a specific warning for neutropenia, febrile neutropenia, or infection with or without severe neutropenia in patients coadministered bevacizumab and platinum-based therapies.]

Coadministration has not been studied. Clodronate is not metabolized and is primarily excreted unchanged by the kidney. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Osteonecrosis of the jaw has been reported in an increasing number of renal cell cancer patients since the use of combined therapies consisting of nitrogen-containing bisphosphonates and antiangiogenic targeted agents. This suggests that angiogenesis suppression might increase the risk of osteonecrosis of the jaw when coadministered with bisphosphonates.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clotrimazole undergoes hepatic metabolism (likely via CYP3A4) and is a moderate inhibitor of CYP3A4. Coadministration is unlikely to cause a clinically significant effect due to the localised effect and low systemic concentrations. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Coadministration has not been studied but a clinically significant interaction is unlikely with the topical use of clotrimazole as it is minimally absorbed. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Cyclophosphamide is activated (major pathway) to 4-hydroxycyclophosphamide by CYPs 2B6 (major), 2C9, and 3A4. Inactivation (minor, 10%) to the neurotoxic chloroacetaldehyde metabolite is performed mainly by CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Daptomycin is eliminated renally with minimal to no active tubular secretion. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other protein therapeutics, daratumumab is expected to be degraded into small peptides and amino acids via catabolic pathways and is not anticipated to alter drug-metabolising enzymes.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetics interaction is unlikely. Dasatinib is a substrate and an inhibitor of cytochrome CYP3A4. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dinutuximab beta is primarily metabolized through catabolic pathways and drug-drug interactions are not expected. Interactions with concomitant medications that are substrates, inducers, or inhibitors of CYP enzymes or drug transporters are unlikely.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dostarlimab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Population PK studies of bevacizumab and doxorubicin predicted no clinically relevant effect on bevacizumab pharmacokinetics. Doxorubicin is mainly eliminated in the bile. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxylamine is metabolized primarily by CYP2D6, CYP1A2, and CYP2C9. Atezolizumab and bevacizumab are primarily metabolized through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Durvalumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Eculizumab, atezolizumab. and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Elotuzumab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Elranatamab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enteral feeds contain polyvalent cations. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enzalutamide is primarily metabolized by CYP2C8, Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Epcoritamab, atezolizumab, and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Epirubicin is glucuronidated by UGT2B7. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols. [Note: patients with severe hepatic impairment should not receive epirubicin.]

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Population PK studies of bevacizumab and erlotinib predicted no clinically relevant effect on either drug. Erlotinib is a substrate for CYP3A4 and P-gp. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected.

The clinical appropriateness of co-prescribing these medications has not been assessed. Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Estramustine is dephosphorylated and minimal data show it not to undergo any form of CYP metabolism. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. However, due to the risk of additive haematological toxicity, haematological parameters should be monitored if coadministered, as per treatment protocols.

Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Atezolizumab and bevacizumab are primarily metabolised through catabolic pathways and drug-drug interactions are not expected. Note: The product label advises immunosuppressants should not be used before starting atezolizumab + bevacizumab, as they may interfere with the efficacy of atezolizumab.